RxDoctor Payments Data

Whitney Harris, APRN

Nurse Practitioner · Cabot, ARNPI 1821767260

Payments from drug & device makers

$1,551in general payments, 2019–2025

Across 70 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$846
  • Vanda Pharmaceuticals Inc.$293
  • AstraZeneca$161
  • Lilly USA, LLC$59
  • Lundbeck LLC$52
  • Otsuka America Pharmaceutical, Inc.$24
  • plus $117 from 8 others

What the payments were for

  • Food & beverage$1,551100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,551 in reported general payments places this provider in the 75th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$414
Medicare patients
16
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$77,833
OzempicSemaglutide28$28,067
JardianceEmpagliflozin23$24,706
EliquisApixaban20$22,765
LinzessLinaclotide16$15,546
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,482
MyrbetriqMirabegron17$7,605
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,368
Combivent RespimatIpratropium/Albuterol Sulfate13$5,452
SymbicortBudesonide/Formoterol Fumarate15$3,505
Gabapentin120$2,119
Albuterol Sulfate HfaAlbuterol Sulfate95$2,107
Pregabalin39$1,846
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,718
Omeprazole130$1,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$59$77,83374 claims
AbbVieLinzess$846$15,54616 claims
GSKTrelegy Ellipta$14$12,48215 claims
AstraZenecaSymbicort$161$3,50515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Cabot

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →